Cardiff Oncology, Inc. (CRDF)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
CRDF price, last 12 months
Key stats
- Previous close
- $1.28
- Open
- $1.30
- Day range
- $1.23 – $1.30
- 52-week range
- $0.7566 – $3.31
- Volume
- 563.4K
- Avg volume (20 days)
- 894.5K
- Market cap
- $96.5M
Performance
Technicals and fundamentals
About Cardiff Oncology, Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $96.5M